Get the Stockscreener App
11.99
2.48%
0.29
Septerna Inc stock is traded at $11.99, with a volume of 362.90K.
It is up +2.48% in the last 24 hours and down -3.85% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$11.70
Open:
$11.84
24h Volume:
362.90K
Relative Volume:
0.85
Market Cap:
$534.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.30%
1M Performance:
-3.85%
6M Performance:
+106.72%
1Y Performance:
+0.00%
1-Day Range:
$11.73
$12.74
1-Week Range:
$10.74
$12.74
52-Week Range:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
11.99 | 516.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Initiated | H.C. Wainwright | Buy |
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
View All
Septerna Inc Stock (SEPN) Latest News
Drawdown in Septerna Inc. May Be Nearing EndJuly 2025 Big Picture & Community Consensus Stock Picks - classian.co.kr
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Cisco Systems (CSCO) - The Globe and Mail
Is There Enough Volume to Lift Septerna Inc.Earnings Recap Summary & Daily Chart Pattern Signal Reports - classian.co.kr
Can Septerna Inc. reach all time highs this year2025 Market Sentiment & Long-Term Growth Plans - newsimpact.co.kr
Why Septerna Inc. stock attracts strong analyst attentionJuly 2025 Action & Free Expert Verified Stock Movement Alerts - classian.co.kr
Is now a turning point for Septerna Inc.July 2025 Spike Watch & Safe Entry Point Identification - Newser
Analyzing Septerna Inc. with multi timeframe chartsWeekly Volume Report & Accurate Entry and Exit Point Alerts - Newser
Is a relief rally coming for Septerna Inc. holdersJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Can you recover from losses in Septerna Inc.July 2025 Retail & Fast Entry High Yield Tips - Newser
What to expect from Septerna Inc. in the next 30 daysTake Profit & Real-Time Chart Breakout Alerts - Newser
Is Septerna Inc. showing signs of accumulationJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
Will Septerna Inc. price bounce be sustainableWeekly Investment Summary & Low Risk High Reward Trade Ideas - Newser
What recovery options are there for Septerna Inc.2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Septerna Inc. outperform the marketSwing Trade & Weekly Top Performers Watchlists - Newser
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Septerna Inc.’s volatility index tracking explained2025 Investor Takeaways & Safe Investment Capital Preservation Plans - Newser
How to track smart money flows in Septerna Inc.2025 Volatility Report & Smart Allocation Stock Tips - Newser
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Automated trading signals detected on Septerna Inc.2025 Top Decliners & Daily Risk Controlled Trade Plans - Newser
RSI Crosses Above 30 for Septerna Inc. — Reversal in SightMarket Growth Report & AI Enhanced Market Trend Forecasts - beatles.ru
Septerna eyes 2026 trial for new hypoparathyroidism treatment - Hypoparathyroidism News
Traders Consider Averaging Down in Septerna Inc.Entry Point & Real-Time Market Sentiment Reports - classian.co.kr
Wells Fargo Maintains Septerna(SEPN.US) With Hold Rating, Maintains Target Price $18 - 富途牛牛
Septerna Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
Septerna (NASDAQ:SEPN) Shares Gap Down Following Weak Earnings - Defense World
Septerna Reports Q2 2025 Financial Results and Progress - TipRanks
Septerna, Inc. shares fall 2.74% intraday despite positive business updates and financial results. - AInvest
Septerna 2025 Q2 Earnings Narrower Losses Amid Sharp Revenue Drop - AInvest
Will Septerna Inc. Stock Benefit from AI and Green Energy Trends3-Day Market Movement Forecast Analysis - Newser
Septerna shares drop as quarterly loss widens despite better-than-expected EPS - Investing.com Canada
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results - The Manila Times
Septerna Reports Q2 2025 Financials, Advances PTH1R Agonist and SEP-631 Programs, Updates Cash Runway - AInvest
Septerna Secures $574M War Chest: Q2 Earnings Show Massive Cash Infusion from Novo Nordisk Deal - Stock Titan
H.C. Wainwright Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $26 - 富途牛牛
Is This a Bottoming Phase for Septerna Inc.Potential Breakout Stock List Published This Week - metal.it
Septerna Appoints Liz Bhatt as New President - TipRanks
What makes Septerna Inc. stock price move sharplySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Can Septerna Inc. rally from current levelsLow Risk Stock Selection Strategy Guide - Newser
What is the dividend policy of Septerna Inc. stockConsistent high-yield stocks - Jammu Links News
What are the latest earnings results for Septerna Inc.Triple-digit return opportunities - Jammu Links News
How does Septerna Inc. compare to its industry peersFree Stock Index Interpretation - Jammu Links News
What are analysts’ price targets for Septerna Inc. in the next 12 monthsUnlock rapid growth potential in your portfolio - Jammu Links News
Is Septerna Inc. a good long term investmentOverwhelming profit margins - Jammu Links News
What markets is Septerna Inc. expanding into Is BACQ stock a good long term investment option - Jammu Links News
What markets is MUFG expanding into Is Septerna Inc. stock a good long term investment optionHigh-profit trading signals - Jammu Links News
What catalysts could drive Septerna Inc. stock higher in 2025Remarkably fast returns - Jammu Links News
What analysts say about Septerna Inc. stockDiscover undervalued stocks ready to soar - Jammu Links News
How volatile is Septerna Inc. stock compared to the marketSuperior stock selection - Jammu Links News
What are the technical indicators suggesting about Septerna Inc.Accelerated capital growth - Jammu Links News
Is it the right time to buy Septerna Inc. stockAchieve breakthrough investment performance - jammulinksnews.com
Why is Septerna Inc. stock attracting strong analyst attentionAchieve consistent profits with expert strategies - Jammu Links News
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 02 '25 |
Option Exercise |
2.76 |
50,000 |
138,000 |
821,907 |
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):